Goldsmith triggers poison-pill rights issued by Crown Zellerbach by buying more stock to take him over 20 percent threshold, potentially blocking a merger with another company
Tag: Crown Zellerbach
Crown Zellerbach’s defense is questioned
Goldsmith boosts stake in Zellerbach to more than 20 percent, casts doubt on poison pill defense
Crown Zellerbach concedes poison pill is irreversible
Zellerbach concedes poison pill is irreversible, Goldsmith says it will hurt restructuring programme
Goldsmith urged to relent by CZ
Crown Zellerbach chairman William Creson urges Goldsmith not to interfere with will of Crown’s shareholders, Goldsmith drops bid
Goldsmith’s battle for Crown Zellerbach control continues
Goldsmith triggers poison-pill rights issued by Crown Zellerbach by buying more stock to take him over 20 percent threshold, potentially blocking a merger with another company
Crown Zellerbach, Goldsmith agree to restructuring truce
Goldsmith and Crown Zellerbach agree to cooperate on restructuring, providing Goldsmith is elected to the board
Goldsmith calls truce in US bid
Goldsmith and Crown Zellerbach agree to cooperate on restructuring, providing Goldsmith is elected to the board
Goldsmith on Crown board after settlement
Goldsmith and Crown Zellerbach agree to cooperate on restructuring, providing Goldsmith is elected to the board
Goldsmith reaches accord with Crown
Goldsmith and Crown Zellerbach agree to cooperate on restructuring, providing Goldsmith is elected to the board
Goldsmith sets a peace accord with Zellerbach
Goldsmith and Crown Zellerbach agree to cooperate on restructuring, providing Goldsmith is elected to the board
Hostile Takeovers easier to swallow than poison pills
Analysis of poison pill defense
Goldsmith faces battle at Crown
Analysis of Goldsmith bid for control of Zellerbach, after election to board
Sir James has fight at Crown
Analysis of Goldsmith bid for control of Zellerbach, after election to board
By Geordie
Goldsmith’s rise to being one of the highest-paid executives in United States
Sir James dodges the poison pill
Analysis of Goldsmith’s success with Zellerbach and poison pill defense
Crown Zellerbach sets plan to divide company in three
Crown Zellerbach unveils plan to split company into three, acknowledging dispute with Goldsmith over restructuring plan
Goldsmith may make another Crown bid
Goldsmith in talks with New York company to mount another bid for Crown Zellerbach, criticises Crown management
Goldsmith is said to buy four blocks of Crown stock
Speculation Goldsmith has bought another 4.8 percent of Crown Zellerbach stocks
Goldsmith raises Crown Zellerbach stake to 35.6 percent, may seek control of company
Goldsmith raises stake in Crown Zellerbach to 35.6 per cent, up from 26 per cent. Goldsmith states he and General Oriental partnership will continue efforts to defeat Crown’s restructuring plan
“Goldsmith raises Crown Zellerbach stake to 35.6 percent, may seek control of company”
Goldsmith raises his stake in Crown to more than 40 percent
Goldsmith raises stake to more than 40 percent in Crown Zellerbach, considers special meeting for shareholders to discuss restructuring
“Goldsmith raises his stake in Crown to more than 40 percent”